NCT07154342招募中3 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Change from Baseline in rTNSS( reflective total nasal symptom scores)
研究概览
简要总结
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the informed consent form.
- •Seasonal allergic rhinitis has been prevalent for at least 2 years.
- •Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past.
- •Positive serum-specific IgE test results.
- •Symptom severity scores for the season met the enrollment criteria.
排除标准
- •Other nasal comorbidities or co-morbidities/states that may be present at the time of screening that affect efficacy determination.
- •Subjects whose allergen exposures in their home or work environments may be expected to change significantly during the trial period.
- •Subjects with poorly controlled recent asthma conditions.
- •Presence of current or past history of infection of special concern, e.g., active tuberculosis, helminthic infections, severe herpes virus infections, etc.
- •Previous use of anti-interleukin 4 receptor alpha subunit (IL4Rα) monoclonal antibody.
- •Have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.
研究组 & 干预措施
Interleukin-4 receptor responder
Experimental
干预措施: GR1802 injection (Biological)
Placebo
Placebo Comparator
干预措施: Placebo (Biological)
结局指标
主要结局
Change from Baseline in rTNSS( reflective total nasal symptom scores)
时间窗: up to 2 weeks
Scores range from 0 to 12, with higher scores indicating more severe symptoms.
次要结局
- Change from Baseline in rTOSS( reflective total ocular symptom scores)(up to 2、4 weeks)
- Change from Baseline in rTNSS(up to 4 weeks)
- Mean change from baseline in iTNSS(instantaneous total nasal symptom scores)(week 2、4)
- Mean change from baseline in iTOSS(instantaneous total ocular symptom scores)(week 2、4)
- Change from baseline in RQLQ(Rhinoconjunctivitis Quality of Life Questionnaire) scores(week2、4)
- Adverse events (AEs)(up to 12 weeks)
- Incidence of ADAs(up to 12 weeks)
- Ctrough(up to 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).Allergic RhinitisNCT06315426Genrix (Shanghai) Biopharmaceutical Co., Ltd.240
已完成
3 期
Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of ActionRhinitis, Allergic, SeasonalNCT00118729GlaxoSmithKline380
已完成
3 期
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)Rhinitis, Allergic, SeasonalNCT00197262GlaxoSmithKline288
已完成
1 期
SUBLIVAC FIX Mite Mixture Dose Tolerability StudyHouse Dust Mite AllergyNCT02345278HAL Allergy81
已完成
2/3 期
Homoeopathic treatment of allergic runny nose and sneezingAllergic rhinitis, unspecified,CTRI/2020/10/028623The Calcutta Homoeopathic Medical College and Hospital60